ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Nichi-Iko Pharmaceutical Co., Ltd.

Business Summary

Nichi-Iko Pharmaceutical Co., Ltd. engages in the manufacturing, sales, distribution, export, import and related activities for various types of pharmaceutical products. The company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems and others. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.

Financial Highlights

Mar 2022 JPYUSD
Gross Profit3,975M35.37M
Operating income-28,152M-250.52M
Income before tax-107,964M-960.76M
Net income-104,875M-933.27M
Diluted EPS-1,552.73-13.81
Dividends Per Share----
Total Assets260,672M2,147.65M
Total liabilities246,753M2,032.98M
Total equity13,536M111.52M
Operating cash flow-24,248M-215.78M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 164,717M 166,592M 190,076M 188,218M 179,060M
Gross Profit 40,803M 33,158M 37,320M 21,245M 3,975M
Operating income 13,200M 7,221M 7,572M -9,867M -28,152M
Income before tax 9,067M 8,903M 7,396M 636M -107,964M
Net income 8,069M 6,864M 5,133M -4,180M -104,875M
EBITDA 22,179M 16,987M 19,443M 3,350M -15,499M
Diluted EPS 142.92 114.03 80.12 -65.27 -1,552.73
Dividends Per Share 30 30 30 25 --
Total Assets 278,364M 306,838M 336,819M 363,572M 260,672M
Total liabilities 190,819M 190,511M 219,644M 251,134M 246,753M
Total equity 87,542M 116,323M 115,827M 111,167M 13,536M
Operating cash flow 18,925M 23,811M 18,450M 5,006M -24,248M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 1,486.18M 1,502.25M 1,748.21M 1,774.68M 1,593.44M
Gross Profit 368.15M 299.00M 343.24M 200.31M 35.37M
Operating income 119.09M 65.11M 69.64M -93.03M -250.52M
Income before tax 81.80M 80.28M 68.02M 5.99M -960.76M
Net income 72.80M 61.89M 47.21M -39.41M -933.27M
EBITDA 200.11M 153.18M 178.82M 31.58M -137.92M
Diluted EPS 1.28 1.02 0.73 -0.61 -13.81
Dividends Per Share 0.27 0.27 0.27 0.23 --
Total Assets 2,617.43M 2,772.17M 3,119.99M 3,290.24M 2,147.65M
Total liabilities 1,794.25M 1,721.19M 2,034.58M 2,272.70M 2,032.98M
Total equity 823.14M 1,050.93M 1,072.91M 1,006.03M 111.52M
Operating cash flow 170.75M 214.71M 169.69M 47.20M -215.78M

Valuation Measures

Mar 2022
Operating margin-15.72%
Profit margin-58.56%

Key executives

  • President & Representative Director: Yuichi Tamura
  • Finance Manager: Naoyuki Okada
  • Head-Compliance Management & Guidance: Yasutomo Sai
  • Director, VP, Head-CSR, ESG & Business Creation: Kenji Akane
  • Executive Officer & Personnel Manager: Keiichi Arakawa


  • Medipal Holdings Corp. (9.7%)
  • Hokuhoku Financial Group, Inc. (3.9%)
  • Nomura Asset Management Co., Ltd. (2.6%)
  • Dimensional Fund Advisors LP (2.2%)
  • The Vanguard Group, Inc. (1.9%)
  • Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.5%)
  • Nichi-Iko Pharmaceutical Co., Ltd. (1.3%)
  • Nikko Asset Management Co., Ltd. (1.2%)
  • Daiwa Asset Management Co. Ltd. (1.2%)

Contact Details

Related Companies

  • Nichi Iko Business Association
  • Nichi Iko Pharmaceutical Co. /Toyama Daini Kojo/
  • Nichi-Iko Gifu Plant Co., Ltd.
  • Nichi-Iko Pharma Tech Co., Ltd.
  • Elmed Co., Ltd.
  • Nichi Iko Pharmaceutical Trust
  • SterRx LLC
  • Nichi-Iko Pharmaceutical Employee Incentive Plan
  • Nichiiko Pharma KK
  • Nichiiko Osaka KK
  • Yakuhan Pharmaceutical Co., Ltd.
  • Sagent Pharmaceuticals, Inc.
  • Kobayashi Pharmaceutical Industries Co. Ltd.
  • Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
  • Oriental Pharmaceutical Co., Ltd.
  • Teikoku Medix Co., Ltd.
  • Japan Galen, Inc.
  • Maruko Pharmaceutical Co. Ltd.
  • Nichiiko Pharmaceutical Employee Stock Pwnership Plan


  • Dr. Reddy's Laboratories Ltd.
  • Cumberland Pharmaceuticals Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
Last Updated on 24 Jun, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more